News

Dr Martin will manage Dynavax’s clinical affairs, including the development of Dynavax’s three current clinical-stage product candidates and three preclinical candidates, which are expected to enter clinical development

The company has recorded total revenues of $15.32 million for the fourth quarter of 2008, an increase of 53%, compared to $10.02 million for the same period of

Net revenue increased 1.5% to $92.2 million for the fourth quarter of 2008, compared with $90.8 million for the prior-year period. For the full year 2008, net revenue

This one-year Phase I Small Business Innovative Research (SBIR) grant will fund the development of novel HIV entry drugs that overcome limitations of current therapies, the company said.

According to Seegene, Seeplex MTB ACE provides simple and fast detection in a single multiplex PCR that uses multiple genetic targets – IS6110 and MPB64. The Seeplex MTB

AppliChem and Akron Biotech are merging forces for the manufacturing and distribution of both companies’ products. Effective March 2, 2009, Akron Biotech has taken over AppliChem’s operations in

The user fee goal date under the Prescription Drug User Fee Act is June 30, 2009. The FDA may grant a new drug application a priority review classification

Bausch & Lomb, the global eye health company, has entered into a licensing agreement with Santen Pharmaceutical, a developer of ophthalmic and anti-rheumatic pharmaceuticals, for the development of

Medtronic, a medical technology company, has signed a definitive agreement to acquire CoreValve, a developer of a transcatheter, transfemoral aortic valve replacement product. This non-surgical alternative offers the